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analysis, alone and in combination with IgG
ELISA, improved the diagnosis of LB by a PLR
of 2–3 compared with the standard two-step
serological approach. This provides a clear
advantage, especially for clinical material with
a high background level of seropositivity,
when difﬁculties are met that are not encountered
when dealing with sporadic cases of Borrelia
infection. However, the above calculations are
not appropriate for areas with a low prevalence
of LB.
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Bacteraemia in cancer patients caused by
colistin-resistant Gram-negative bacilli after
previous exposure to ciproﬂoxacin and ⁄or
colistin
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The recent publication in CMI by Michalopoulos
et al. [1], as well as that of Li et al. [2], focused on
the increasing role of colistin (COL) for the
treatment of infections caused by multiresistant
Gram-negative bacilli. COL has been reported to
be the only antibiotic effective against multire-
sistant strains of Pseudomonas aeruginosa or Acine-
tobacter baumanii in cases when all other available
antibiotics, including carbapenems, were ineffec-
tive [1,2]. However, Landman et al. [3] reported
the emergence of resistance to polymyxin B in 13
patients with P. aeruginosa (PA) infection in the
USA, with MICs up to 8 mg ⁄L.
As long ago as 1995, we described an outbreak
of meropenem-resistant P. aeruginosa infections in
a cancer centre, in which >15 patients were
infected with bacteraemia caused by P. aeruginosa
susceptible only to COL and amikacin [4].
Between October 2004 and July 2005, we observed
ten patients in the intensive care unit (ICU) of
St Elisabeth Cancer Institute, Bratislava, Slovakia,
who were hospitalised with post-operative peri-
tonitis (wound infection and bacteraemia) and
infected with COL-resistant Gram-negative bac-
teria. The ﬁrst patient was admitted to the ICU in
September 2004, and was infected initially with
P. aeruginosa with a COL MIC of 4 mg ⁄L, which
increased after therapy to 8 mg ⁄L. Eight of the ten
patients stayed in the ICU on several occasions,
all ten were treated previously with ciproﬂoxacin,
and ﬁve with colistin. Five of the ten patients died
(four with uncontrolled sepsis; one with under-
lying disease and bacteraemia).
Eighteen COL-resistant organisms were isolat-
ed within the context of polymicrobial bacterae-
mia (Table 1). Previous exposure to colistin and
ciproﬂoxacin probably inﬂuenced the develop-
ment of resistance. Two species (P. aeruginosa,
Citrobacter freundii; patient 3) showed stepwise
increases in MICs (from 0.25 or 2 to 8 mg ⁄L)
during treatment with colistin (Table 1). For the
remaining patients (16 organisms), the bacterial
isolates were resistant (MICs 8–64 mg ⁄L) on ﬁrst
isolation (Table 1). The recommended breakpoint
MIC for colistin is 2 mg ⁄L in France, 4–8 mg ⁄L in
the UK, 4–8 mg ⁄L according to the NCCLS, and
4 mg ⁄L in Germany [2]. Therefore we considered
isolates with an MIC ‡ 8 mg ⁄L to be resistant.
DNA ﬁngerprinting was not performed, but none
of the resistance phenotypes were identical, and
we therefore assumed that each isolate was
different. For eight patients, none of the tested
antibiotics retained in-vitro activity, and ﬁve of
these patients died. Emerging resistance in our
hospital to COL provides further evidence for the
onset of the post-antibiotic era in P. aeruginosa,
Stenotrophomonas maltophilia and some Enterobac-
teriaceae.
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The effect of implementing the British
Thoracic Society community-acquired
pneumonia guidelines on antibiotic
prescribing and costs in a UK teaching
hospital
10.1111/j.1469-0691.2006.01387.x
The recent article in CMI by Ooesterheert et al.
[1] predicted a 23% increase in antibiotic use
following hypothetical implementation of the
British Thoracic Society (BTS) community-
acquired pneumonia (CAP) guidelines at a
teaching hospital in The Netherlands. We have
recently evaluated the implementation of a
management pathway to improve the time to
administration and the appropriateness of
empirical antibiotics for CAP at a UK teaching
hospital.
The intervention was based on the BTS
guidelines and emphasised the link between
severity assessment and appropriate antibiotic
Table 1. Characteristics of patients from whom colistin-resistant Gram-negative bacilli were isolated
Patient (month ⁄ year of
treatment ⁄diagnosis)
MIC of COL initially and COL
MIC during therapy
(day ⁄month of isolation)
Susceptibility
to other antibiotics
Pre-treatment
with other
antibiotics Outcome
Pt. 1 (12 ⁄ 2004–01 ⁄ 2005) Acinetobacter baumannii IMI, SUL, PIP ⁄TAZ CIP Recovered
Post-operative peritonitis MIC 8
Pt. 2 (04 ⁄ 2005–05 ⁄ 2005) Pseudomonas. aeruginosa Resistant to PIP ⁄TAZ, AMI, CIP, SUL Died
Pneumonia, peritonitis MIC 8 (8 ⁄ 4); MIC 8 (3 ⁄ 5) CTZ, MER, SUL, CIP PIP ⁄TAZ, CTZ
Pt. 3 (12 ⁄ 2004–02 ⁄ 2005) Citrobacter freundii Resistant to all antibiotics tested CIP, CTX Recovered
Septic shock MIC 0.25 (20 ⁄ 12); MIC 0.5 (22 ⁄ 12); MER, COL
Decubital ulcer MIC 4 (10 ⁄ 1); MIC 4 (18 ⁄ 1); MIC 8 (26 ⁄ 1)
Febrile neutropenia P. aeruginosa MIC 2 (21 ⁄ 12); Resistant to all antibiotics tested CIP, PIP ⁄TAZ
Nosocomial pneumonia MIC 4 (31 ⁄ 12); MIC 8 (4 ⁄ 1); MIC 4 (10 ⁄ 1); CEP, AMI
MIC 4 (17 ⁄ 1); MIC 4 (26 ⁄ 1); MIC 8 (31 ⁄ 1)
Escherichia coli MIC 8 (26 ⁄ 1)
Pt. 4 (08 ⁄ 2004–09 ⁄ 2004) Ps. aeruginosa MIC 8 (2 ⁄ 8); MIC 4 (16 ⁄ 8); Susceptible to AMI (MIC 16 mg ⁄L) CIP, TMZ, MER, Recovered
Pneumonia, peritonitis MIC 4 (3 ⁄ 9); MIC 8 (15 ⁄ 9) CTX, PIP ⁄TAZ
Klebsiella pneumoniae MIC 8 (2 ⁄ 8) Susceptible to AMI (8 mg ⁄L)
Acinetobacter spp. MIC 8 (15 ⁄ 9) Resistant to all antibiotics tested
Pt. 5 (03 ⁄ 2005) P. aeruginosa MIC 8 Resistant to all antibiotics tested CIP, MER Died
Peritonitis E. coli MIC 8
Pt. 6 (04 ⁄ 2005) K. pneumoniae MIC 64 Resistant to all antibiotics tested, COL, CIP Died
Liver abscess including MER, AMI, CIP, CTZ, PIP ⁄TAZ
Pt. 7 (05 ⁄ 2005) Stenotrophomonas maltophilia Susceptible to TMZ, CMP COL, PIP ⁄TAZ, Died
Peritonitis MIC 8 (17 ⁄ 5); MIC 8 (2 ⁄ 8); MIC 4 (16 ⁄ 8); CIP
MIC 4 (3 ⁄ 9); MIC 8 (15 ⁄ 9)
Pt. 8 (06 ⁄ 2005) S. maltophilia MIC 64 (3 ⁄ 6) Resistant to all antibiotics tested, COL, CIP, Died
P. aeruginosa MIC 64 (10 ⁄ 6) including CIP, TMZ, AMI PIP ⁄TAZ
Pt. 9 (06 ⁄ 2005) P. aeruginosa MIC 8 Resistant to all tested antibiotics COL, IMI Died
Peritonitis K. pneumoniae MIC 8
Pt. 10 (06 ⁄ 2005) K. pneumoniae MIC 8 Resistant to all tested antibiotics COL, CIP Died
Peritonitis P. aeruginosa MIC 8
COL, colistin; CMP, chloramphenicol; CIP, ciproﬂoxacin; SUL, cefoperazone ⁄ sulbactam; CTZ, ceftazidime; CEP, cefepime; CTX, cefotaxime; PIP ⁄TAZ, piperacillin ⁄ tazo-
bactam; MER, meropenem; TMZ, co-trimoxazole; AMI, amikacin; IMI, imipenem.
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